310 related articles for article (PubMed ID: 18297393)
1. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Breast Cancer Res Treat; 2009 Jan; 113(2):321-6. PubMed ID: 18297393
[TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Breast Cancer Res Treat; 2007 Jan; 101(2):185-90. PubMed ID: 16897434
[TBL] [Abstract][Full Text] [Related]
3. Long-term transvaginal ultrasonographic endometrial follow-up in postmenopausal breast cancer patients with tamoxifen treatment.
Nahari C; Tepper R; Beyth Y; Flex D; Figer A; Cohen I
Gynecol Oncol; 1999 Aug; 74(2):222-6. PubMed ID: 10419735
[TBL] [Abstract][Full Text] [Related]
4. Ultrasonographic measurement of endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients.
Cohen I; Beyth Y; Azaria R; Flex D; Figer A; Tepper R
BJOG; 2000 Sep; 107(9):1083-7. PubMed ID: 11002949
[TBL] [Abstract][Full Text] [Related]
5. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors.
Garuti G; Cellani F; Centinaio G; Montanari G; Nalli G; Luerti M
Gynecol Oncol; 2006 Nov; 103(2):599-603. PubMed ID: 16750259
[TBL] [Abstract][Full Text] [Related]
6. Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.
Morales L; Timmerman D; Neven P; Konstantinovic ML; Carbonez A; Van Huffel S; Ameye L; Weltens C; Christiaens MR; Vergote I; Paridaens R
Ann Oncol; 2005 Jan; 16(1):70-4. PubMed ID: 15598941
[TBL] [Abstract][Full Text] [Related]
7. The effect of tamoxifen on the endometrium, serum lipids and hypothalamus pituitary axis in the postmenopausal breast cancer patients.
Kavak ZN; Binöz S; Ceyhan N; Pekin S
Acta Obstet Gynecol Scand; 2000 Jul; 79(7):604-7. PubMed ID: 10929963
[TBL] [Abstract][Full Text] [Related]
8. Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology.
Morales L; Paridaens R; Timmerman D; Neven P
Clin Cancer Res; 2006 Sep; 12(18):5603. PubMed ID: 17000698
[No Abstract] [Full Text] [Related]
9. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
Gerber B; Krause A; Reimer T; Mylonas I; Makovitzky J; Kundt G; Janni W
Clin Cancer Res; 2006 Feb; 12(4):1245-50. PubMed ID: 16489080
[TBL] [Abstract][Full Text] [Related]
10. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen.
Mourits MJ; Van der Zee AG; Willemse PH; Ten Hoor KA; Hollema H; De Vries EG
Gynecol Oncol; 1999 Apr; 73(1):21-6. PubMed ID: 10094875
[TBL] [Abstract][Full Text] [Related]
11. Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound, color flow Doppler, hysteroscopic and histological study.
Exacoustos C; Zupi E; Cangi B; Chiaretti M; Arduini D; Romanini C
Ultrasound Obstet Gynecol; 1995 Dec; 6(6):435-42. PubMed ID: 8903921
[TBL] [Abstract][Full Text] [Related]
12. Endometrial thickness of postmenopausal breast cancer patients treated with tamoxifen.
Salazar EL; Paredes A; Calzada L
Gynecol Endocrinol; 2005 Dec; 21(6):312-6. PubMed ID: 16390778
[TBL] [Abstract][Full Text] [Related]
13. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound.
Gerber B; Krause A; Müller H; Reimer T; Külz T; Makovitzky J; Kundt G; Friese K
J Clin Oncol; 2000 Oct; 18(20):3464-70. PubMed ID: 11032586
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer.
Garuti G; Grossi F; Centinaio G; Sita G; Nalli G; Luerti M
Eur J Obstet Gynecol Reprod Biol; 2007 May; 132(1):101-6. PubMed ID: 16678960
[TBL] [Abstract][Full Text] [Related]
15. Endometrial thickness and ovarian cysts as measured by ultrasound in asymptomatic postmenopausal breast cancer patients on various adjuvant treatments including tamoxifen.
Lindahl B; Andolf E; Ingvar C; Liedman R; Ranstam J; Willén R
Anticancer Res; 1997; 17(5B):3821-4. PubMed ID: 9427787
[TBL] [Abstract][Full Text] [Related]
16. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
17. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women.
Marttunen MB; Cacciatore B; Hietanen P; Pyrhönen S; Tiitinen A; Wahlström T; Ylikorkala O
Br J Cancer; 2001 Apr; 84(7):897-902. PubMed ID: 11286468
[TBL] [Abstract][Full Text] [Related]
18. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
19. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
20. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings.
Hann LE; Giess CS; Bach AM; Tao Y; Baum HJ; Barakat RR
AJR Am J Roentgenol; 1997 Mar; 168(3):657-61. PubMed ID: 9057510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
